source
- Replimune secures FDA approval for RP1 therapy in advanced melanoma as Eli Lilly reports strong Q2 earningsReplimune announced that the FDA has granted market approval for its oncolytic immunotherapy RP1, aimed at treating advanced melanoma. The decision follows two earlier rejections and a contentious…
- Definium's oral LSD candidate passes first Phase 3 trial in generalized anxiety disorderDefinium Therapeutics announced that its oral LSD candidate has successfully completed a Phase 3 trial in generalized anxiety disorder. The study met its primary endpoints, marking the first of tw…